SBIR/STTR Research Award

Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases

Award identifier 412e95754e3d22b7a62924e114656bc96d0a6995da0ce3d593668144c622c59eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$414,721

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INTEGRAL MOLECULAR INC
Proposal award date
2018-09-01
Contract end date
2020-05-31
UEI
DY9KSWE8EJB8
Solicitation number
PAS17-064
Topic code
NIA

Research abstract

ABSTRACT Alzheimerandapos s diseaseADand other neurodegenerative diseases are a major cause of death and disability for older Americanswith a US prevalence of more thanmillionAs AD currently cannot be cured or preventedthere is an urgent need for effective treatments targeting underlying disease processesA major roadblock in treatment development has been the lack of good targetsAlthough pathologically importantamyloid beta plaques and tau tangles are not easily druggableand clinical trials of therapeutics targeting these proteins directly have largely failedRecent genome wide association studies have identified a link between a growing number of modulatory proteins on neuroimmune cellsparticularly on the surface of microglia and astrocytesthat are linked to the risk of developing ADThe identification of new proteins with neuroimmunomodulatory activities could enable an entirely new generation of therapeutic targets with the potential to treatdelayand possibly even prevent AD and other neurodegenerative diseases PROJECT NARRATIVE The human health significance of the proposed work is the identification of new targets on neuroimmune cells for treating Alzheimerandapos s diseaseADand other neurodegenerative diseasesCurrentlyno drug on the market targets the underlying disease process of ADand therapeutics against traditional targets in AD have repeatedly failed in late stage clinical trialsThese factors highlight an urgent need to identify new therapeutic targets in ADMost importantlythese new targets should be relevant in the earlyasymptomatic stages of disease where intervention can slowstopor prevent disease progressionNeuroimmune cell modulators offer this potential

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

48 SBIR/STTR records share this UEI (2002–2025). Reported award amounts total $32,839,788. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.